Smart blood test guides fight against tough lymphoma
NCT ID NCT07511114
Summary
This study is testing a new, personalized approach to treat an aggressive type of blood cancer called double-expression lymphoma. It compares a standard chemotherapy (CR-CHOP) against a strategy where a blood test (ctDNA) is used after the first treatment cycle to guide which additional drugs a patient receives. The goal is to see if this tailored method leads to more patients achieving complete remission and staying cancer-free longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DOUBLE-EXPRESSOR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai, Shanghai
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.